Adaptive immunity against COVID-19

The adaptive immune response has often been described as the key player in determining the severity of COVID-19 disease. The COVID-19 outcomes seem to be dependent upon the B-cell– and T-cell–mediated adaptive immunity to SARS-CoV-2. Coordinated CD4+ T-cell, CD8+ T-cell, and antibody responses are protective, whereas, the uncoordinated immune responses are associated with the severe form of COVID-19. Multiple human vaccines in clinical trials to counteract SARS-CoV-2 is based upon the neutralizing antibodies directed at the spike protein. The potential therapeutic and preventive monoclonal antibodies used in human clinical trials are also based on the viral neutralization. The vaccines can generate high levels of neutralizing antibodies comparable with or greater than those seen in sera samples from patients. The induction of sufficient CD4+ helper T-cells and inclusion of vaccine boosts, may be needed to maintain levels of anti–SARS-CoV-2 neutralizing antibodies. The COVID-19 vaccines are in rapid development by utilizing the knowledge of adaptive immunity against COVID-19, and we are hopeful to get the effective and safe vaccines for the public use very soon.

Download Full-text

A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response

Vaccines ◽

10.3390/vaccines9050431 ◽

2021 ◽

Vol 9 (5) ◽

pp. 431

Author(s):

Duško Lainšček ◽

Tina Fink ◽

Vida Forstnerič ◽

Iva Hafner-Bratkovič ◽

Sara Orehek ◽

...

Keyword(s):

Immune Response ◽

Neutralizing Antibodies ◽

Specific Antigen ◽

Adaptive Immune Response ◽

Adaptive Immune System ◽

T Cell Response ◽

Viral Neutralization ◽

Adaptive Immune ◽

Lumazine Synthase ◽

Antibody Titers

The response of the adaptive immune system is augmented by multimeric presentation of a specific antigen, resembling viral particles. Several vaccines have been designed based on natural or designed protein scaffolds, which exhibited a potent adaptive immune response to antigens; however, antibodies are also generated against the scaffold, which may impair subsequent vaccination. In order to compare polypeptide scaffolds of different size and oligomerization state with respect to their efficiency, including anti-scaffold immunity, we compared several strategies of presentation of the RBD domain of the SARS-CoV-2 spike protein, an antigen aiming to generate neutralizing antibodies. A comparison of several genetic fusions of RBD to different nanoscaffolding domains (foldon, ferritin, lumazine synthase, and β-annulus peptide) delivered as DNA plasmids demonstrated a strongly augmented immune response, with high titers of neutralizing antibodies and a robust T-cell response in mice. Antibody titers and virus neutralization were most potently enhanced by fusion to the small β-annulus peptide scaffold, which itself triggered a minimal response in contrast to larger scaffolds. The β-annulus fused RBD protein increased residence in lymph nodes and triggered the most potent viral neutralization in immunization by a recombinant protein. Results of the study support the use of a nanoscaffolding platform using the β-annulus peptide for vaccine design.

Download Full-text

Persisting adaptive immunity to SARS-CoV-2 in Lower Austria

10.1101/2021.02.18.21251551 ◽

2021 ◽

Author(s):

Dennis Ladage ◽

Oliver Harzer ◽

Peter Engel ◽

Hannes Winkler ◽

Ralf J. Braun

Keyword(s):

Immune Response ◽

T Cell ◽

Adaptive Immunity ◽

Immunoglobulin A ◽

Cell Activity ◽

Adaptive Immune Response ◽

Population Based ◽

Immune Memory ◽

Adaptive Immune ◽

Specific Immunoglobulin

The prevalence and persistence of adaptive immunity responses following a SARS-CoV-2 infection provides insights into potential population immunity. Adaptive immune responses comprise of antibody-based responses as well as T cell responses mainly addressing viruses and virus-infected human cells, respectively. A comprehensive analysis of both types of adaptive immunity is essential to follow population-based SARS-CoV-2-specific immunity. In this study, we assessed SARS-CoV-2-specific immunoglobulin A (IgA) levels, SARS-CoV-2-specific immunoglobulin G (IgG) levels, and SARS-CoV-2-specific T cell activities in patients who recovered from a COVID-19 infection in spring and autumn 2020. Here we observed a robust and stable SARS-CoV-2-specific adaptive immune response in both groups with persisting IgA and IgG levels as well as stable T cell activity. Moreover, there was a positive correlation of a lasting immune response with the severity of disease. Our data give evidence for a persisting adaptive immune memory, which suggest a continuing immunity for more than six months post infection.

Download Full-text

The Interplay between Bluetongue Virus Infections and Adaptive Immunity

Viruses ◽

10.3390/v13081511 ◽

2021 ◽

Vol 13 (8) ◽

pp. 1511

Author(s):

Daniel Rodríguez-Martín ◽

Andrés Louloudes-Lázaro ◽

Miguel Avia ◽

Verónica Martín ◽

José M. Rojas ◽

...

Keyword(s):

T Cells ◽

T Cell ◽

Adaptive Immunity ◽

Bluetongue Virus ◽

Viral Infections ◽

Adaptive Immune Response ◽

Γδ T Cells ◽

Neutralizing Antibody ◽

Immune Mechanisms ◽

Adaptive Immune

Viral infections have long provided a platform to understand the workings of immunity. For instance, great strides towards defining basic immunology concepts, such as MHC restriction of antigen presentation or T-cell memory development and maintenance, have been achieved thanks to the study of lymphocytic choriomeningitis virus (LCMV) infections. These studies have also shaped our understanding of antiviral immunity, and in particular T-cell responses. In the present review, we discuss how bluetongue virus (BTV), an economically important arbovirus from the Reoviridae family that affects ruminants, affects adaptive immunity in the natural hosts. During the initial stages of infection, BTV triggers leucopenia in the hosts. The host then mounts an adaptive immune response that controls the disease. In this work, we discuss how BTV triggers CD8+ T-cell expansion and neutralizing antibody responses, yet in some individuals viremia remains detectable after these adaptive immune mechanisms are active. We present some unpublished data showing that BTV infection also affects other T cell populations such as CD4+ T-cells or γδ T-cells, as well as B-cell numbers in the periphery. This review also discusses how BTV evades these adaptive immune mechanisms so that it can be transmitted back to the arthropod host. Understanding the interaction of BTV with immunity could ultimately define the correlates of protection with immune mechanisms that would improve our knowledge of ruminant immunology.

Download Full-text

SARS-CoV-2 Human T cell Epitopes: adaptive immune response against COVID-19.

Cell Host & Microbe ◽

10.1016/j.chom.2021.05.010 ◽

2021 ◽

Author(s):

Alba Grifoni ◽

John Sidney ◽

Randi Vita ◽

Bjoern Peters ◽

Shane Crotty ◽

...

Keyword(s):

Immune Response ◽

T Cell ◽

Adaptive Immune Response ◽

T Cell Epitopes ◽

Adaptive Immune ◽

Human T Cell

Download Full-text

IMGT® Biocuration and Comparative Analysis of Bos taurus and Ovis aries TRA/TRD Loci

Genes ◽

10.3390/genes12010030 ◽

2020 ◽

Vol 12 (1) ◽

pp. 30

Author(s):

Perrine Pégorier ◽

Morgane Bertignac ◽

Viviane Nguefack Ngoune ◽

Géraldine Folch ◽

Joumana Jabado-Michaloud ◽

...

Keyword(s):

Immune Response ◽

Comparative Analysis ◽

T Cell ◽

T Cell Receptors ◽

Bos Taurus ◽

Homo Sapiens ◽

Adaptive Immune Response ◽

Ovis Aries ◽

Cell Receptors ◽

Adaptive Immune

The adaptive immune response provides the vertebrate immune system with the ability to recognize and remember specific pathogens to generate immunity, and mount stronger attacks each time the pathogen is encountered. T cell receptors are the antigen receptors of the adaptive immune response expressed by T cells, which specifically recognize processed antigens, presented as peptides by the highly polymorphic major histocompatibility (MH) proteins. T cell receptors (TR) are divided into two groups, αβ and γδ, which express distinct TR containing either α and β, or γ and δ chains, respectively. The TRα locus (TRA) and TRδ locus (TRD) of bovine (Bos taurus) and the sheep (Ovis aries) have recently been described and annotated by IMGT® biocurators. The aim of the present study is to present the results of the biocuration and to compare the genes of the TRA/TRD loci among these ruminant species based on the Homo sapiens repertoire. The comparative analysis shows similarities but also differences, including the fact that these two species have a TRA/TRD locus about three times larger than that of humans and therefore have many more genes which may demonstrate duplications and/or deletions during evolution.

Download Full-text

SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses

10.1101/2021.03.10.21253299 ◽

2021 ◽

Author(s):

Raymond T. Suhandynata ◽

Nicholas J. Bevins ◽

Jenny T. Tran ◽

Deli Huang ◽

Melissa A. Hoffman ◽

...

Keyword(s):

Immune Response ◽

Immune Responses ◽

Neutralizing Antibodies ◽

Natural Infection ◽

Adaptive Immune Response ◽

Antibody Assay ◽

Adaptive Immune Responses ◽

Adaptive Immune ◽

Previous Infection ◽

A Cell

AbstractBackgroundThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated.MethodsThe ability of four commercial SARS-CoV-2 serology platforms to detect previous infection or vaccination were evaluated using a cohort of 53 SARS-CoV-2 PCR-positive patients, 89 SARS-CoV-2-vaccinated healthcare workers (Pfizer or Moderna), and 127 SARS-CoV-2 negative patients. Serology results were compared to a cell based SARS-CoV-2 pseudovirus (PSV) neutralizing antibodies assay.ResultsThe Roche S-(spike) antibody and Diazyme neutralizing antibodies (NAbs) assays detected adaptive immune response in 100.0% and 90.1% of vaccinated individuals who received two-doses of vaccine (initial and booster), respectively. The Roche N-(nucleocapsid) antibody assay and Diazyme IgG assay did not detect adaptive immune response in vaccinated individuals. The Diazyme Nabs assay correlated with the PSV SARS-CoV-2 ID50 neutralization titers (R2= 0.70), while correlation of the Roche S-antibody assay was weaker (R2= 0.39). Median PSV SARS-CoV-2 ID50 titers more than doubled in vaccinated individuals who received two-doses of the Moderna vaccine (ID50: 597) compared to individuals that received a single dose (ID50: 284).ConclusionsThe Roche S-antibody and Diazyme NAbs assays robustly detected adaptive immune responses in SARS-CoV-2 vaccinated individuals and SARS-CoV-2 infected individuals. The Diazyme NAbs assay strongly correlates with the PSV SARS-CoV-2 NAbs in vaccinated individuals. Understanding the reactivity of commercially available serology platforms is important when distinguishing vaccination response versus natural infection.SummaryThe Roche S (spike protein)-antibody and Diazyme neutralizing-antibodies (NAbs) assays were evaluated for their clinical utility in the detection of SARS-CoV-2 related adaptive immune responses by testing SARS-CoV-2 PCR-confirmed patients, SARS-CoV-2-vaccinated individuals, and SARS-CoV-2-negative individuals. Commercial serology results were compared to results generated using a cell-based SARS-CoV-2 pseudovirus (PSV) NAbs assay and previously validated SARS-CoV-2 commercial serology assays (Roche N (nucleocapsid protein) antibody and Diazyme IgG). We demonstrate that the Roche S-antibody and Diazyme NAbs assays detected adaptive immune response in SARS-CoV-2 vaccinated individuals and the presence of SARS-CoV-2 PSV NAbs. The Roche S-antibody assay had an observed positive percent agreement (PPA) of 100% for individuals who received two doses of the Pfizer or Moderna vaccine. By contrast, the Roche N assay and Diazyme IgG assay did not detect vaccine adaptive immune responses. Our findings also indicate that the Diazyme NAbs assay correlates strongly with the levels of SARS-CoV-2 ID50 neutralization titers using the PSV Nab assay in vaccinated individuals.

Download Full-text

Covid-19 Vaccines and their Interchangeability Could be Effective in Developing Countries Like India to Generate Stronger Adaptive Immune Response in Large Population

10.47363/jmhc/2021(3)156 ◽

2020 ◽

pp. 1-3

Author(s):

Saif Ali ◽

Keyword(s):

Immune Response ◽

Developing Countries ◽

Clinical Trials ◽

Large Population ◽

Adaptive Immune Response ◽

Adverse Side Effects ◽

Adaptive Immune ◽

The People ◽

Blood Clots ◽

The World

Vaccine considered as a boon for every individual across the world in the time of pandemic situation. India has developed its own vaccine which shows promising results. Receiving vaccine does not mean that we are completely immune to the disease. Covishield shows some rare but adverse side effects of blood clots in those people having thrombocytopenia. Covaxin has not recorded any such cases as it is of inactivated type. But, the manufacturers of the vaccine have not established the longevity of protection against COVID-19. Unavailability of vaccines in India could pose a serious impact on the lives of the people. Government of India and Medical authorities should take clinical trials and make decision on interchangeability of vaccines as soon as possible.

Download Full-text

Introduction to Clinical Immunology: Overview of the Immune Response, Autoimmune Conditions, and Immunosuppressive Therapeutics for Rheumatic Diseases

10.2310/im.1328 ◽

2016 ◽

Author(s):

Steven K. Lundy ◽

Alison Gizinski ◽

David A. Fox

Keyword(s):

Immune Response ◽

Immune System ◽

T Cell ◽

Immune Responses ◽

Autoimmune Diseases ◽

Adaptive Immunity ◽

Cell Populations ◽

Hematopoietic Stem ◽

Innate And Adaptive Immunity ◽

Adaptive Immune

The immune system is a complex network of cells and mediators that must balance the task of protecting the host from invasive threats. From a clinical perspective, many diseases and conditions have an obvious link to improper functioning of the immune system, and insufficient immune responses can lead to uncontrolled acute and chronic infections. The immune system may also be important in tumor surveillance and control, cardiovascular disease, health complications related to obesity, neuromuscular diseases, depression, and dementia. Thus, a working knowledge of the role of immunity in disease processes is becoming increasingly important in almost all aspects of clinical practice. This review provides an overview of the immune response and discusses immune cell populations and major branches of immunity, compartmentalization and specialized immune niches, antigen recognition in innate and adaptive immunity, immune tolerance toward self antigens, inflammation and innate immune responses, adaptive immune responses and helper T (Th) cell subsets, components of the immune response that are important targets of treatment in autoimmune diseases, mechanisms of action of biologics used to treat autoimmune diseases and their approved uses, and mechanisms of other drugs commonly used in the treatment of autoimmune diseases. Figures show the development of erythrocytes, platelets, lymphocytes, and other immune system cells originating from hematopoietic stem cells that first reside in the fetal liver and later migrate to the bone marrow, antigen–major histocompatibility complex recognition by T cell receptor control of T cell survival and activation, and Th cells as central determinants of the adaptive immune response toward different stimuli. Tables list cell populations involved in innate and adaptive immunity, pattern recognition receptors with known ligands, autoantibody-mediated human diseases: examples of pathogenic mechanisms, selected Food and Drug Administration–approved autoimmune disease indications for biologics, and mechanism of action of biologics used to treat autoimmune diseases. This review contains 3 highly rendered figures, 5 tables, and 64 references.

Download Full-text

Adaptive immunity

Oxford Textbook of Medicine ◽

10.1093/med/9780199204854.003.050103 ◽

2010 ◽

pp. 224-234

Author(s):

Paul Klenerman

Keyword(s):

Infectious Disease ◽

Immune Response ◽

Pattern Recognition ◽

Adaptive Immunity ◽

Adaptive Response ◽

Critical Role ◽

Adaptive Immune Response ◽

Structural Features ◽

Adaptive Immune ◽

Single Organism

Following the innate immune response, which acts very rapidly, the adaptive immune response plays a critical role in host defence against infectious disease. Unlike the innate response, which is triggered by pattern recognition of pathogens, i.e. features that are common to many bacteria or viruses, the adaptive response is triggered by structural features—known as antigens or epitopes—that are typically unique to a single organism....

Download Full-text

Adaptive immunity

Oxford Textbook of Medicine ◽

10.1093/med/9780198746690.003.0040 ◽

2020 ◽

pp. 325-336

Author(s):

Paul Klenerman

Keyword(s):

Immune Response ◽

Immune Responses ◽

Adaptive Immunity ◽

Innate Immune Response ◽

Molecular Basis ◽

Adaptive Immune Response ◽

Antigenic Specificity ◽

Adaptive Immune Responses ◽

Research Attention ◽

Adaptive Immune

The adaptive immune response is distinguished from the innate immune response by two main features: its capacity to respond flexibly to new, previously unencountered antigens (antigenic specificity), and its enhanced capacity to respond to previously encountered antigens (immunological memory). These two features have provided the focus for much research attention, from the time of Jenner, through Pasteur onwards. Historically, innate and adaptive immune responses have often been treated as separate, with the latter being considered more ‘advanced’ because of its flexibility. It is now clear this not the case, and in recent years the molecular basis for these phenomena has become much better understood.

Download Full-text